CYP19A1 and neoplasm: The assessment of ER expression holds crucial clinical significance as it enables targeted hormonal therapy, such as selective ER modulators (e.g., tamoxifen) or aromatase inhibitors (e.g., anastrozole), which effectively reduce the estrogen signaling pathway and inhibit tumor growth.